Interview: CrystalGenomics, First Korean Bioventure To ‘Go All The Way’
Executive Summary
After reaching milestones by launching a novel osteoarthritis drug and licensing out an AML candidate to a US partner, CrystalGenomics’ CEO talks to Scrip about what else is in store for the South Korean bioventure in 2017 and beyond.
You may also be interested in...
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods
Fallout from the withdrawal of Vioxx (rofecoxib) will likely have an impact on post-marketing surveillance methods for COX-2 inhibitors and other drugs
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.